Clinical Trials Logo

Filter by:
NCT ID: NCT06428500 Recruiting - Clinical trials for Advanced Solid Tumor

QTX3046 in Patients With KRAS G12D Mutations

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.

NCT ID: NCT06428097 Recruiting - Clinical trials for Heart Transplant Infection

Levothyroxine Supplementation for Heart Transplant Recipients

Levo
Start date: March 29, 2024
Phase: Phase 1
Study type: Interventional

This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.

NCT ID: NCT06427915 Recruiting - Healthy Nutrition Clinical Trials

Studying Glucose and Appetite Response With Alternatives to Soda Pop

SODA-SWAP
Start date: May 15, 2024
Phase: N/A
Study type: Interventional

The primary aim of this clinical trial is to determine the acute effects of OLIPOP (a lower sugar, high fiber prebiotic soda) consumption, compared to consumption of a commercially available sugar-sweetened soda pop, on blood glucose in response to the beverages alone and in combination with a carbohydrate-rich mixed lunch meal in free-living, generally healthy adults.This study will consist of one screening/randomization clinic visit (day 0) and one follow-up clinic visit (day 5), with participants consuming study products on their own (e.g., at home) following an assigned treatment sequence on days 1, 2, 3, and 4. The main questions answered by this trial are the impacts of a prebiotic rich soda versus a traditional soda on: 1) blood glucose levels with and without a meal, 2) perceived hunger levels, 3) perceived alertness levels and 4) total caloric intake.

NCT ID: NCT06426628 Recruiting - Lung Cancer Clinical Trials

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

NIGHTINGALE
Start date: July 18, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: - Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? - Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer? Participants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.

NCT ID: NCT06426498 Recruiting - Healthy Clinical Trials

tFUS Induced Transient Scotoma for Individual Dosing

Start date: June 20, 2024
Phase: N/A
Study type: Interventional

The purposes of this research study is to: 1. Develop a technique of transcranial Focused Ultrasound Stimulation (tFUS) where meaningful effects on the brain can be easily measured. 2. Use this technique to measure threshold for effective tFUS in individuals. 3. Determine whether disruption of conscious visual detection, versus non-conscious visually-guided behavior have different thresholds for disruption with tFUS.

NCT ID: NCT06426303 Recruiting - Clinical trials for Alcohol Use Disorder

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

ABSTAIN
Start date: June 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to identify sex-specific biomarkers that confer greater susceptibility for Alcohol Use Disorder (AUD) and differentiate how treatment response varies by sex in people with Alcohol Use Disorder. The main questions it aims to answer are: - How does trauma affect emotion regulation, inflammation, and limbic function, and what are the sex-dependent effects of NTX (Naltrexone) on these aspects? - What is the mechanism of Naltrexone (NTX), and how does it potentially moderate reductions in alcohol use through changes in or interactions between emotion regulation, inflammation, or limbic system function? Participants will - Be consented and will undergo comprehensive screening for eligibility criteria - Complete behavioral assessments and neuropsychological assessments, as well as neurocognitive assessments and neuroimaging measures - Provide urine samples for a urine drug screen (UDS) and urine pregnancy test (for women), and have blood and a cheek swab collected and stored in the repository - Take a study drug once daily for 12 weeks and track drug usage and effects in a study journal - Undergo weekly assessment calls and bi-weekly medical follow-up safety exams Researchers will compare naltrexone to placebo in AUD to see if naltrexone is effective in reducing alcohol cravings and promoting abstinence. Researchers will also compare baseline measures between AUD and Healthy Controls.

NCT ID: NCT06426238 Recruiting - Pain Clinical Trials

Self-reported and Experimental Pain in Patients Undergoing Orthodontic Treatment

Start date: January 3, 2024
Phase:
Study type: Observational

Pressure Pain Threshold (PPT) is defined as the minimum force applied to an area that is perceived as pain. PPT is considered an objective measurement tool to assess pain levels. Studies have assessed the difference in pain levels between clear aligners and fixed appliances using subjective pain scales. No study has utilized PPT to evaluate the difference in pain between aligners and fixed braces at different time points. This study will aim to compare the self- reported and experimental pain perception between the clear aligner and fixed appliance therapies during the phase of crown alignment and to assess how long pain is perceived in the following five days from the adjustment of the appliance.

NCT ID: NCT06425991 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

MajesTEC-10
Start date: June 7, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).

NCT ID: NCT06425939 Recruiting - Exercise Clinical Trials

Exploring the Relationship Between Heart Rate Variability (HRV), Training Load, and Exercise Performance

Start date: May 8, 2024
Phase: N/A
Study type: Interventional

Heart rate variability (HRV) is a measure of the variation in time between each heartbeat. It is an indirect and ubiquitous biomarker of performance readiness and recovery measured by most consumer-grade wearable fitness trackers. However, there is little documented on the relationship between HRV, training load, and performance measures in the Real-World. Whoop wrist-worn activity trackers have been validated against the gold-standard Electrocardiography (ECG) for HRV and HR measurements. Whoop leverages photoplethysmography (PPG) technology to continuously track (HR, HRV, respiratory rate, energy expenditure) and provides, daily, individual insights, trends, and coaching to improve strain, sleep, and recovery. Research has demonstrated that heart rate variability (HRV) guided training may be more optimal compared to predetermined training for aerobic exercise improvements. The purpose of this study is to assess the feasibility of providing personalized training recommendations based on HRV measured by a consumer-grade wearable (Whoop) in a real-world setting to better understand the HRV relationship with performance.

NCT ID: NCT06425926 Recruiting - Solid Tumor Clinical Trials

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Start date: May 9, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).